Jean-Yves Coste

Jean-Yves Coste, MBA

Medical Aesthetics Expert & Senior Healthcare Director

Michel Dyens & Co.


Jean-Yves Coste, has dedicated himself to the Healthcare sector for more than 25 years both in Senior Investment Banking and in Executive positions within a corporate environment.

Currently Senior Healthcare Director at Michel Dyens & Co., a Franco-American Investment Banking Firm based in Paris and New York with a focus on cross-border M&A, capital raisings and partnerships. My Group covers in the specialty generics, biotech, prophylactic and therapeutic vaccines and medtech spaces as well as Specialty Pharma, Healthcare Services such as Clinics and Spas, Medical Aesthetics, Dermo-cosmetics, Rx and OTC  Dermatology and Energy-Based Devices, Regenerative Medicine, Diagnostics and Digital Health with a strong focus on this booming sector, especially in international M&A, JVs, Partnerships and Capital Raisings deal.

From 2008 to 2010, he was Senior M&A Adviser at Bryan, Garnier a leading investment banking Firm with a focus on healthcare, media, renewables, luxury, consumer goods, IT, Digital and telecom. Previously, he headed the European Healthcare Investment Banking at Cowen, based in London and reinforced Cowen’s Healthcare franchise in Europe. In 2003, Jean-Yves moved to Boehringer Ingelheim to lead its M&A department at the German headquarters. Over four years, he gained valuable expertise and excellent access to the management of one of the leading Top 20 Big Pharma. In 1996, Jean-Yves joined Deutsche Bank in Frankfurt and developed a sector specialization in Healthcare, particularly Midcap Pharma, Specialty Pharma, OTC and Biotech; from 2000 to 2003, he worked at Deutsche Banc. Alex Brown in in New York and Baltimore (MD – USA), responsible for spearheading the development of biotech cross border M&A execution franchise.

Jean-Yves led-managed the origination and execution of a number of Capital Markets and M&A transactions in the ophthalmology sector (IPO of Novagali in 2010, buy-sides for Nicox regarding Eupharmed in Italy, Doliage and Marinomed in 2013/2014, then Divestiture of Nicox’ Europe operations to Gho Capital in 2016) and was involved in a number of M&A and Licensing as well as Hybrid Equity Capital Raising / Partnership Deals.

Gained relevant expertise in transactions involving the prevention, therapy and patient-centric management of age-related chronic, degenerative diseases and the area of regenerative and rejuvenation medicine in all cross-sectional segments from Biotech, Molecular Diagnostics, Specialty Pharma, Medical and Energy-Based-Devices and has developed a differentiated know-how in realizing M&A and Capital Raising transactions in the Medical Aesthetics Sector with a strong focus on dermal filler companies as well as on beauty instrumentation in medtech, dermocosmetics and mesotherapy and skin rejuvenation companies, regenerative and reconstructive medicine and medical spas offering facial and body remodeling services as shown in the Croma US- JV with Hugel CORP, Neauvia-Abris Capital 51% Divestment, Bloomage-Vivacy, Bloomage-Revitacare, Universkin-Croma, Simone Mahler, Delife-Menarini and BMG-Pierre Fabre deals and repeat transactions at the service of Ophthalmology pure-player Nicox.

Jean-Yves graduated from HEC with a major in Finance and holds an MBA from INSEAD in the Investment Banking Track.